Group
Companies
History
Business model
Mission and vision
Corporate values
Commitment to sport
Research
Pharmaceutical Research
Sucrosomial Technology
Cetylated Fatty Acids
Quality and certifications
Brands
PharmaNutra
SiderAL
SiderAL Forte
SiderAL Folico
Cardio SiderAL
SiderAL Med
Cetilar Crema
ApportAL
UltraMag
Gestalys DHA
Novomega
Bonecal
DiKappa2
Junia Pharma
Alesco
Investor Relations
INVESTOR
Shares study and research
Share capital and Shareholders
Financial statements
Presentations
SDIR
Corporate events
Company presentation
Notice of meetings
AIM admission document
MTA prospectus
PRESS
Press releases
Press review
Governance
Board of Directors and Committees
Company documents
Internal dealing
Shareholders’ meeting
Statutory auditors and Audit firm
Sharholders Agreements
Media
News
Social commitment
Careers
Work with us
Job offers
Group
Companies
History
Business model
Mission and vision
Corporate values
Commitment to sport
Research
Pharmaceutical Research
Sucrosomial Technology
Cetylated Fatty Acids
Quality and certifications
Brands
PharmaNutra
SiderAL
SiderAL Forte
SiderAL Folico
Cardio SiderAL
SiderAL Med
Cetilar Crema
ApportAL
UltraMag
Gestalys DHA
Novomega
Bonecal
DiKappa2
Junia Pharma
Alesco
Investor Relations
INVESTOR
Shares study and research
Share capital and Shareholders
Financial statements
Presentations
SDIR
Corporate events
Company presentation
Notice of meetings
AIM admission document
MTA prospectus
PRESS
Press releases
Press review
Governance
Board of Directors and Committees
Company documents
Internal dealing
Shareholders’ meeting
Statutory auditors and Audit firm
Sharholders Agreements
Media
News
Social commitment
Careers
Work with us
Job offers
it
en
24 October 2019 |
PHARMANUTRA GROUP STATUTORY FINANCIAL STATEMENT 31/12/2018
